Negative serology (antibody test) for the following infectious diseases:\r\n* Human immunodeficiency virus (HIV) type 1 and 2\r\n* Human T-cell leukemia virus (HTLV) type 1 and 2 (mandatory in United States [US] but optional in Canada and Europe)\r\n* Hepatitis B surface antigen\r\n* Hepatitis C antibody
Positive for HIV, hepatitis B, hepatitis C, syphilis or human T Cell leukemia virus (HTLV).
EXCLUSION - PROCUREMENT: Active infection with human immunodeficiency virus (HIV), human T-lymphotropic virus (HTLV), hepatitis B virus (HBV), hepatitis C virus (HCV) (can be pending at this time)
Positive for HIV, hepatitis B, hepatitis C, syphilis or human T cell leukemia virus (HTLV).
Donors who are HIV-1, HIV-2, human T-lymphotropic virus (HTLV)-1, HTLV-2 seropositive or with active hepatitis B or hepatitis C virus infection
DONOR: Infectious disease screening performed within 30 days prior to stem cell mobilization per federal guidelines and is:\r\n* Seronegative for HIV 1+2 antibody (Ab) and/or HIV polymerase chain reaction (PCR), human T-cell leukemia virus (HTLV) I/II Ab, hepatitis B virus surface antigen (HBsAg), hepatitis B virus surface antibody (HBcAb), hepatitis C virus (HCV) Ab\r\n* Negative rapid plasma reagin (RPR) for syphilis
DONOR: Sero-positive for HIV-1 & 2 antibody, HTLV-I & II antibody, hepatitis B virus (HBV) and HCV
DONOR: Active hepatitis, positive for human T-cell lymphotropic virus (HTLV), or HIV on donor viral screen
DONOR: Performance of a donor infectious disease screen panel including cytomegalovirus (CMV) antibody, hepatitis B surface antigen, hepatitis B core antibody, hepatitis C antibody, human immunodeficiency virus (HIV) polymerase chain reaction (PCR), HIV ½ antibody, human T-lymphotropic virus antibody (HTLVA) ½ antibody, rapid plasma reagin (RPR), treponema and trypanosoma Cruzi (T. Cruzi), plus nucleic acid testing (NAT) testing (hepatitis B virus [HBV], hepatitis C virus [HCV], West Nile virus [WNV], HIV by nucleic acid method); or per current panel – must be negative for HIV and active hepatitis B
CELL PROCUREMENT: Patients with the following systemic viral infections will be excluded: active human immunodeficiency virus (HIV), human T-lymphotropic virus (HTLV), hepatitis B virus (HBV), hepatitis C virus (HCV) (tests can be pending at the time of cell procurement; only those samples confirming lack of active infection will be used to generate transduced cells); Note: to meet eligibility subjects are required to be negative for HIV antibody or HIV viral load, negative for HTLV1 and 2 antibody or polymerase chain reaction (PCR) negative for HTLV1 and 2, negative for hepatitis B surface antigen, or negative for HCV antibody or HCV viral load
DONOR: Positivity for HIV, hepatitis B (hepatitis B virus [HBV]), hepatitis C (hepatitis C virus [HCV]), human T-cell lymphotropic virus (HTLV-I/II)
DONOR: Chronic viral infection including active hepatitis B, hepatitis C, HIV, or human T-lymphotropic virus (HTLV)-1/2
DONOR: Positive for hepatitis, human T-lymphotropic virus (HTLV), or HIV on donor viral screen
Any positive history for human immunodeficiency virus/acquired immunodeficiency syndrome (HIV/AIDS), human T-cell lymphotropic virus (HTLV), hepatitis B or hepatitis C virus indicating acute or chronic infection
PRIOR TO CELL PROCUREMENT: Active infection with human immunodeficiency virus (HIV), human T-cell lymphotropic virus (HTLV), hepatitis C virus (HCV) (can be pending at the time of cell procurement; only those samples confirming lack of active infection will be used to generate transduced cells) defined as not being well controlled on therapy; patients are required to have negative HIV antibody or negative HIV viral load, negative HTLV1 and 2 antibodies, negative HCV antibody or viral load
Has a known history of human immunodeficiency virus (HIV) (positive HIV 1/2 antibodies); human T-cell lymphotropic virus (HTLV) 1 antibody (HTLV1) and/or HTLV2; active hepatitis B (e.g., hepatitis B virus surface antigen [HBsAg] reactive) or hepatitis C (e.g., hepatitis C virus [HCV] ribonucleic acid [RNA] [qualitative] is detected); patients with prior hepatitis B virus (HBV) vaccination (anti-HBs positive, HBsAg negative, anti-HBc negative) will NOT be excluded
Patients who test positive for human immunodeficiency virus (HIV), hepatitis B surface antigen, hepatitis B core antibody, hepatitis C antibody, human T-lymphotropic virus (HTLV) I or II antibody, or are both rapid plasma reagin (RPR) and fluorescent treponemal antibody (FTA) positive are excluded
DONOR: Donor has undergone serologic testing for transmissible diseases as per blood banking guidelines for organ and tissue donors; tests include but are not limited to: hepatitis B surface antigen, hepatitis B surface antibody, hepatitis B core antibody, hepatitis C antibody, Epstein-Barr virus antibody, human immunodeficiency virus (HIV), human T-cell leukemia virus (HTLV) I and II, varicella zoster (herpes zoster), herpes simplex antibody, cytomegalovirus antibodies, syphilis (rapid plasma reagin [RPR] profile) for adolescents and adults, measles for pediatric patients, West Nile virus, Chagas screen, and toxoplasma antibodies
DONOR: Negative testing for relevant communicable diseases\r\n* Testing for infectious disease includes:\r\n** Hepatitis B surface antigen (HBsAg)\r\n** Hepatitis B core antibody (Anti-HBc)\r\n** Hepatitis C antibody (Anti-HCV)\r\n** HIV 1 & 2 antibody (Anti-HIV-1, 2 plus O)\r\n** Human T-lymphotropic virus (HTLV) I/II antibody (Anti-HTLV I/II)\r\n** Rapid plasma reagin (RPR) (Syphilis Treponema pallidum [TP])\r\n** Cytomegalovirus (CMV) (Capture CMV)\r\n** Multiplex (MPX) for: HepB (HBV-PCR), HepC (HCV-PCR), HIV (HIV-PCR)\r\n** Nucleic acid testing (NAT) for West Nile Virus (WNV-PCR)\r\n** Trypanosoma cruzi (T. Cruzi) - enzyme immunoassay (EIA) (Chagas)\r\n* Laboratory testing for infectious disease will be performed at the time of initial donor assessment and must be performed within 30 days of the HSC collection; if multiple collections of HSC occur from the same donor, the infectious disease testing shall be performed within 30 days prior to each collection
No known history of human immunodeficiency virus (HIV) 1 and 2, human T-lymphotropic virus (HTLV)-1, or active hepatitis B or hepatitis C
Human immunodeficiency virus (HIV), human T-cell lymphotropic virus type 1 (HTLV-1), hepatitis B virus (HBV), and hepatitis C virus (HCV) negative
DONOR: Seronegative for human immunodeficiency virus (HIV) antigen (Ag), HIV 1+2 antibody (Ab), human T-lymphotropic virus (HTLV) I/II Ab, hepatitis B surface antigen (HBsAg), hepatitis B core antibody (HBcAb) (immunoglobulin [Ig]M and IgG), hepatitis C virus (HCV) Ab, rapid plasma reagin (RPR) for syphilis within 30 days of apheresis collection
DONOR: Hepatitis A, B and C, HIV 1 and 2, human T-lymphotropic virus (HTLV), varicella zoster virus (VZV), Epstein-Barr virus (EBV), herpes simplex virus (HSV), West Nile virus, Syphilis Treponema, T cruzi (Chagas), cytomegalovirus (CMV), and the MPX nucleic acid test (NAT) individual donor testing (IDT) (human immunodeficiency virus [HIV]/hepatitis C virus [HCV]/hepatitis B virus [HBV]) will be tested as per national standard of care guidelines for transplant donors; donors who are HIV positive will be excluded; donors who are positive by serology for Hepatitis B or C are eligible as long as polymerase chain reaction (PCR) for ribonucleic acid (RNA)/deoxyribonucleic acid (DNA) is negative
Human immunodeficiency virus (HIV) positive (recipients who are positive for hepatitis B [hepatitis B virus (HBV)], hepatitis C [hepatitis C virus (HCV)] or human T-cell lymphotropic virus [HTLV]-I/II are not excluded from participation)
Positive for human immunodeficiency virus (HIV), hepatitis B virus (HBV), hepatitis C virus (HCV), human T-lymphotropic virus 1 (HTLV1) and/or HTLV2
Seroreactivity for human immunodeficiency virus (HIV), human T-lymphotropic virus type I (HTLV I) or II, hepatitis B virus (HBV), hepatitis C virus (HCV)
Uncontrolled infection, including human immunodeficiency virus (HIV), human T-lymphotropic virus (HTLV)-1, hepatitis B or hepatitis C viremia
DONOR: Donor is to be negative for human immunodeficiency virus (HIV) antigen (Ag), HIV 1+2 antibody (Ab), human T-lymphotropic virus (HTLV) I/II Ab, hepatitis B surface antigen (HbsAg), hepatitis B core antibody (HbcAb) (immunoglobulin [Ig]M [combination screening test] and IgG), hepatitis C virus (HCV), and rapid plasma reagin (RPR) for syphilis within 30 days of apheresis collection; if the only donor is positive for Hepatitis B or C or syphilis, the recipient must be notified - the recipient may proceed if Principal Investigator (PI), recipient and donor agree and there is no alternative related donor
History of human immunodeficiency virus (HIV), hepatitis B, hepatitis C and human t-lymphotropic virus (HTLV)
DONOR: Must be free from risk factors for, and no clinical evidence of, infection due to relevant communicable disease agents and diseases including: human immunodeficiency virus; hepatitis B virus; hepatitis C virus; human transmissible spongiform encephalopathy, including Creutzfeldt-Jakob disease; treponema pallidum and human T-cell lymphotropic virus (HTLV) 1 and 2
DONOR: Must be human immunodeficiency virus (HIV)-1&2 antibody, HTLV-I&II antibody, hepatitis B virus (HBV) and hepatitis C virus (HCV) sero-negative, by Food and Drug Administration (FDA) licensed test
Known infection with human immunodeficiency virus (HIV), human T-cell lymphotropic virus (HTLV)-I, hepatitis B, or hepatitis C
Active infection with human immunodeficiency virus (HIV), human T-cell lymphotropic virus (HTLV), hepatitis B virus (HBV), hepatitis C virus (HCV) (can be pending at this time)
DONOR: Human T-lymphotropic virus (HTLV)/HIV(+) or hepatitis B or C antigen(+) donors
DONOR: Donor must meet all Robert Wood Johnson (RWJ) Blood Services requirements for hematopoietic stem cell donation including:\r\n* Age >= 18 years old;\r\n* Normal hemogram (white blood cells [WBC] 4.0-10.0 x 10^3/mm^3; platelet count 150,000 to 440,000/mm^3 ; hemoglobin/hematocrit; 12.5-18 g/dl, 38 to 54% \r\n* Not pregnant or lactating;\r\n* Not human immunodeficiency virus (HIV)-1, HIV-2, hepatitis C virus (HCV), hepatitis B core or human T-cell lymphotropic virus (HTLV)-I/II seropositive; hepatitis B surface antigen (HB S ag) (-); meet other infectious disease screening criteria utilized by RWJ Blood Services;\r\n* No uncontrolled infections, other medical or psychological/social conditions, or medications that might increase the likelihood of patient or donor adverse effects or poor outcomes;\r\n* Meet other blood bank criteria for blood product donation (as determined by RWJ Blood Center screening history and laboratory studies)
DONORS: Performance of a donor infectious disease screen panel including cytomegalovirus (CMV) antibody, hepatitis B surface antigen, hepatitis B core antibody, hepatitis C antibody, human immunodeficiency virus (HIV) 1/2 antibody, human T-cell leukemia-lymphoma virus (HTLV) 1/2 antibody, Treponema, and trypanosoma cruzi (T. Cruzi) plus hepatitis B virus (HBV), hepatitis C virus (HCV), West Nile virus (WNV), HIV by nucleic acid testing (NAT); or per current standard institutional donor screen – must be negative for HIV and active hepatitis B
Immunocompromised patients (other than that related to the use of corticosteroids) including patients known to be human immunodeficiency virus (HIV), human T-cell lymphotropic virus (HTLV), hepatitis B (HepB), or hepatitis C (HepC) positive
DONOR: Serologies for human immunodeficiency virus (HIV) antigen (Ag), HIV 1 and HIV 2 antibody (Ab), human T-cell lymphotropic virus (HTLV) 1 and HTLV 2 Ab, hepatitis B surface antigen (sAg) or polymerase chain reaction (PCR)+, or hepatitis C Ab or PCR+, syphilis (Treponema) screen and HIV 1 and hepatitis C by NAT (nucleic acid testing) have been collected prior to apheresis
DONOR: Seronegative for human immunodeficiency virus (HIV)-1 ribonucleic acid (RNA) polymerase chain reaction (PCR), HIV 1 and HIV 2 antibody (ab), human T-cell lymphotropic virus type (HTLV)-1 and HTLV-2 ab; PCR positive (+) or surface antigen (sAg) hepatitis B; or PCR+ or sAg for hepatitis C; negative for the Treponema palladum antibody syphillis screen; and negative for HIV-1 and hepatitis C by nucleic acid testing (NAT) within 30 days of apheresis collection; in the case that Treponema (T) palladum antibody tests are positive, donors must:\r\n* Be evaluated and show no evidence of syphilis infection of any stage by physical exam and history\r\n* Have completed effective antibiotic therapy to treat syphilis\r\n* Have a documented negative non treponemal test (such as rapid plasma reagin [RPR]) or in the case of a positive non treponemal test must be evaluated by an infectious disease expert to evaluate for alternative causes of test positivity and confirm no evidence of active syphilitic disease
Patients testing positive for human immunodeficiency virus (HIV) titre, hepatitis B surface antigen, hepatitis B core antibody, hepatitis C antibody, human T-lymphotropic virus (HTLV) I or II antibody, or both rapid plasma reagin (RPR) and fluorescent treponemal antibody (FTA) positive are excluded
Patients testing positive for human immunodeficiency virus (HIV) titre, hepatitis B surface antigen, hepatitis B core antibody, hepatitis C antibody, human T-lymphotropic virus (HTLV) I or II antibody, or both rapid plasma reagin (RPR) and fluorescent treponemal antibody (FTA) positive are excluded
DONOR: Positive or reactive test results for Food and Drug Administration (FDA)-mandated relevant communicable diseases (HIV, hepatitis B [hep B], hepatitis C, human T-cell lymphotropic virus [HTLV], Syphilis, Trypanosoma [T.] cruzi)
Human immunodeficiency virus (HIV), hepatitis C virus (HCV), hepatitis B virus (HBV) or human T-lymphotropic virus (HTLV) I/II infections
Active infection with human immunodeficiency virus (HIV), human T-lymphotropic virus (HTLV), hepatitis B virus (HBV), hepatitis C virus (HCV) (can be pending at this time)
DONOR: Donor has undergone serologic testing for transmissible diseases as per blood banking guidelines for organ and tissue donors; tests include but are not limited to: hepatitis B surface antigen (HepBsAg), hepatitis B surface antibody (HepBsAb), hepatitis B core antibody (HepBcAb), hepatitis C (HepC) antibody, human immunodeficiency virus (HIV), human T-lymphotropic virus (HTLV) I and II, varicella zoster virus (VZV), cytomegalovirus (CMV) and Venereal Disease Research Laboratory (VDRL), West Nile virus and Chagas screen; donor must have normal negative test results for HIV, HTLV I and II, and West Nile virus; donor exposure to other viral pathogens will be discussed on a case-by-case basis by the investigators
Exclusions for the leukapheresis procedure (this can be performed at a later time of symptoms resolve): \r\n* Infection, with or without antibiotic treatment\r\n* Recent hepatitis exposure (hepatitis B or C antigenemia)\r\n* Pregnancy or nursing\r\n* HIV or human T-lymphotropic virus (HTLV) infection\r\n* Positive result on standard test for syphilis (STS)
Immunocompromised patients (other than that related to the use of corticosteroids) including patients known to be human immunodeficiency virus (HIV), human T-cell lymphotropic virus (HTLV), hepatitis B (HepB), or hepatitis C (HepC) positive
DONOR: Donors who are HIV-1, HIV-2, human T-lymphotropic virus (HTLV)-1, HTLV-2 seropositive or with active hepatitis B or hepatitis C virus infection
Seroreactivity for human immunodeficiency virus (HIV), human T-lymphotropic virus (HTLV) I or II, hepatitis B virus (HBV), hepatitis C virus (HCV)
Known or tests positive for human immunodeficiency virus (HIV), human T-cell leukemia virus (HTLV-1), hepatitis B or hepatitis C.
DONOR: Donors must not be seropositive for HIV 1 and 2, hepatitis B surface antigen, hepatitis B core antibody, human T-lymphotropic virus (HTLV) antibody, cytomegalovirus (CMV) immunoglobulin (Ig)M, or rapid plasma reagin (RPR) (Treponema)
Known infection with human immunodeficiency virus (HIV), human T-lymphotropic virus 1 (HTLV-I), hepatitis B, or hepatitis C
MATCHED RELATED DONOR: Donors must be human immunodeficiency virus (HIV) negative, human T-cell lymphotropic virus (HTLV) negative, hepatitis B virus surface antigen (HBsAg) negative
Positive test results for human immunodeficiency virus (HIV), human T-lymphotropic virus 1 (HTLV1), hepatitis C or chronic hepatitis B
DONOR: Virology testing including cytomegalovirus (CMV), human immunodeficiency virus (HIV), Epstein–Barr virus (EBV), human T-lymphotropic virus (HTLV), rapid plasma reagin (RPR), hepatitis A, B and C will be performed within 30 days of donation
Donor has undergone serologic testing for transmissible diseases as per blood banking guidelines for organ and tissue donors; tests include but are not limited to: hepatitis B surface antigen (HepBsAg), hepatitis B surface antibody (HepBsAb), hepatitis B core antibody (HepBcAb), HepC antibody, human immunodeficiency virus (HIV), human T-cell lymphotropic virus (HTLV) I and II, varicella zoster virus (VZV), cytomegalovirus (CMV) and Venereal Disease Research Laboratory test (VDRL), and West Nile virus; donor must have normal negative test results for HIV, HTLV I and II, and West Nile virus
HIV or human T-lymphotropic virus (HTLV) I/II positive, hepatitis C or chronic active hepatitis B
DONOR: not human immunodeficiency virus (HIV)-1, HIV-2, hepatitis C virus (HCV), hepatitis B core or human T-lymphotropic virus (HTLV)-I/II seropositive; hepatitis B surface antigen (HB S ag) (-); meet other infectious disease screening criteria utilized by NBAH Blood Center
Active symptomatic fungal, bacterial and/or viral infection including positive serologies for human immunodeficiency virus (HIV), H\\human T-lymphotropic virus 1 (HTLV-1), 2, hepatitis C virus (HCV) or hepatitis B virus (HBV) (acute or chronic infection based on Center for Disease Control and Prevention [CDC] guidelines) within 30 days of registration; (antibody, antigen and nucleic acid tests acceptable, depending on institutional standards)
Positive hepatitis serology (HBV, HCV) or positive HIV or Human T Cell Leukemia Virus (HTLV) testing
Uncontrolled infection, including human immunodeficiency virus (HIV), human T-cell lymphotropic virus type 1 (HTLV-1), hepatitis B or hepatitis C viremia
DONOR: Human T-cell lymphotropic virus (HTLV)/human immunodeficiency virus (HIV)(+) or hepatitis B or C antigen(+) donors
DONOR: Serologies for human immunodeficiency virus (HIV) antigen (Ag), HIV 1 and HIV 2 antibody (Ab), human T-lymphotropic virus type I (HTLV 1) and HTLV 2 Ab, hepatitis B surface antigen (sAg) or polymerase chain reaction positive (PCR+), or hepatitis C Ab or PCR+, syphilis (Treponema) screen and HIV 1 and hepatitis C by nucleic acid testing (NAT) have been collected prior to apheresis
DONOR: Positive for human immunodeficiency virus (HIV), active hepatitis B (hepatitis B virus [HBV]), hepatitis C (hepatitis C virus [HCV]) or human T?cell lymphotropic virus (HTLV?I/II)
Active infection with human immunodeficiency virus (HIV), human T-lymphotropic virus (HTLV), hepatitis B virus (HBV), hepatitis C virus (HCV) (can be pending at the time of cell procurement; only those samples confirming lack of active infection will be used to generate transduced cells); active infection is defined as not being well controlled on therapy (Note: to meet eligibility subjects are required to be negative for HIV antibody or HIV viral load, negative for HTLV1 and 2 antibody, negative for hepatitis B surface antigen, or negative for HCV antibody or HCV viral load)
DONOR: All donors will be screened for the following:\r\n* Human immunodeficiency virus (HIV) I\r\n* HIV II\r\n* Hepatitis surface antigen (HbsAg)\r\n* Hepatitis B core antibody (HBc)\r\n* Hepatitis C virus (HCV)\r\n* Cytomegalovirus (CMV)\r\n* Syphilis\r\n* Human T-lymphotropic virus (HTLV I/II)\r\n* Epstein-Barr virus (EBV) and adenovirus immunoglobulin G (IgG) when feasible
Positive viral test of the donor for HIV-1, HIV-2, hepatitis B virus (HBV), hepatitis C virus (HCV), Treponema pallidum, human T-lymphotropic virus (HTLV) 1 (if tested), HTLV-2 (if tested), West Nile virus (WNV; if tested), or Zika virus (if tested)
